Revenue
0 USD
2017 Q1 · USD
Exact inputs and evidence
- Revenue: 0 USD Source
Fundies. English
NANOANTIBIOTICS, INC.
EDGAR73 filing records in this dataset, filed from 2013-08-15 to 2026-08-13. Reported financial figures are available; chart coverage varies by period.
Latest quarter
Operating cash flow
-128 thousand USD
2017 Q1 · USD
Exact inputs and evidence
- Operating Cash Flow: -128012 USD Source
- Cash and cash equivalents
- 8.98 million USD Source
Exact value
8977370 USD
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 7.54 million shares Source
Exact value
7542638 shares
Reported share-count change
294.03% · 5.63 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Operating cash flow
-19 million USD
2025-07-01 – 2026-06-30
Exact inputs and evidence
- Operating cash flow: -3023874 USD · 2025-07-01 – 2025-09-30 Source
- Operating cash flow: -7461591 USD · 2025-07-01 – 2025-12-31 Source
- Operating cash flow: -3023874 USD · 2025-07-01 – 2025-09-30 Source
- Operating cash flow: -14903200 USD · 2025-07-01 – 2026-03-31 Source
- Operating cash flow: -7461591 USD · 2025-07-01 – 2025-12-31 Source
- Operating cash flow: -19024806 USD · 2025-07-01 – 2026-06-30 Source
- Operating cash flow: -14903200 USD · 2025-07-01 – 2026-03-31 Source
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-08-13.
Financial data available through: 2026-06-30.
Coverage by financial measure
- revenue: No compatible figures in this window
- Operating income: 11 of 11 periods available· newest 2026-06-30
- Net income: 10 of 11 periods available· newest 2026-06-30
- Operating cash flow: 11 of 11 periods available· newest 2026-06-30
- capital expenditure: No compatible figures in this window
- Total assets: 11 of 11 periods available· newest 2026-06-30
- Total liabilities: 11 of 11 periods available· newest 2026-06-30
- Current assets: 11 of 11 periods available· newest 2026-06-30
- Current liabilities: 11 of 11 periods available· newest 2026-06-30
- Cash and cash equivalents: 5 of 11 periods available· newest 2026-06-30
- long term debt: No compatible figures in this window
- Shares outstanding: 11 of 11 periods available· newest 2026-06-30
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
−USD 4.53 millionPrior period
−USD 17.54 million
–
Current period
−USD 22.07 million
–
Exact inputs and evidence
-22072863 − -17542120 = -4530743 USD
-17542120 USD · 2024-07-01 – 2025-06-30
Inspect prior input Prior source-22072863 USD · 2025-07-01 – 2026-06-30
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 399Prior period
−USD 19.03 million
–
Current period
−USD 19.02 million
–
Exact inputs and evidence
-19024806 − -19025205 = 399 USD
-19025205 USD · 2024-07-01 – 2025-06-30
Inspect prior input Prior source-19024806 USD · 2025-07-01 – 2026-06-30
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue, Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Not enough comparable data to show this history.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2017 2016-07-01 – 2017-06-30 | −USD 1.33 million Exact valueExact value: -1330672 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 623,615 Exact valueExact value: -623615 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2018 2017-07-01 – 2018-06-30 | −USD 2.43 million Exact valueExact value: -2434117 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 621,341 Exact valueExact value: -621341 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2019 2018-07-01 – 2019-06-30 | Unavailable Not reported for this period. | −USD 2.5 million Exact valueExact value: -2501577 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2020 2019-07-01 – 2020-06-30 | −USD 16.68 million Exact valueExact value: -16676768 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 1.63 million Exact valueExact value: -1628228 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2021 2020-07-01 – 2021-06-30 | −USD 130.25 million Exact valueExact value: -130249204 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 10.45 million Exact valueExact value: -10453047 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2022 2021-07-01 – 2022-06-30 | −USD 26.08 million Exact valueExact value: -26084468 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 18.99 million Exact valueExact value: -18990850 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2023 2022-07-01 – 2023-06-30 | −USD 50.26 million Exact valueExact value: -50255815 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 40.25 million Exact valueExact value: -40252881 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2024 2023-07-01 – 2024-06-30 | −USD 32.12 million Exact valueExact value: -32120533 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 27.95 million Exact valueExact value: -27945024 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2024-07-01 – 2025-06-30 | −USD 17.54 million Exact valueExact value: -17542120 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 19.03 million Exact valueExact value: -19025205 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2026 2025-07-01 – 2026-06-30 | −USD 22.07 million Exact valueExact value: -22072863 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 19.02 million Exact valueExact value: -19024806 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
73 filings · 2,078 latest values · 2,078 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001580149, 1580149, BIVI, BIVIW, bivi, edgar:1580149
Also known as BIOVIE INC., BIOVIE INC. (F/K/A NANOANTIBIOTICS, INC.), BioVie Inc., NANOANTIBIOTICS, INC.